Autonomix Medical, Inc. (AMIX)
NASDAQ: AMIX · Real-Time Price · USD
0.8450
-0.0250 (-2.87%)
At close: Dec 5, 2025, 4:00 PM EST
0.8447
-0.0003 (-0.04%)
After-hours: Dec 5, 2025, 7:52 PM EST
Company Description
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system.
The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.
It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders.
Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Autonomix Medical, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Bradley Hauser |
Contact Details
Address: 21 Waterway Avenue, Suite 300 The Woodlands, Texas 77380 United States | |
| Phone | 713 588 6150 |
| Website | autonomix.com |
Stock Details
| Ticker Symbol | AMIX |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001617867 |
| CUSIP Number | 05330T106 |
| ISIN Number | US05330T2050 |
| Employer ID | 47-1607810 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Bradley Hauser | Chief Executive Officer and President |
| Walter V. Klemp | Executive Chairman |
| Lori H. Bisson | Executive Vice Chairman |
| Dr. Robert Schwartz M.D. | Co-Founder and Chief Medical Officer |
| Landy Toth | Co-Founder and Chief Technology Officer |
| David A. Robins | Co-Founder and Director |
| Trent N. Smith CPA | Executive Vice President and Chief Financial Officer |
| Jennifer Cook | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 19, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 3, 2025 | 8-K | Current Report |
| Oct 6, 2025 | 424B3 | Prospectus |
| Sep 30, 2025 | EFFECT | Notice of Effectiveness |
| Sep 29, 2025 | UPLOAD | Filing |
| Sep 23, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 12, 2025 | DEF 14A | Other definitive proxy statements |